GPRC5D PET/CT scan for plasma cell disorders
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses a special PET/CT scan to look for a protein called GPRC5D in people with plasma cell disorders (like multiple myeloma). The scan might help doctors see where the disease is in the body. Healthy volunteers can also join to help compare results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a plasma cell disorder (like multiple myeloma) or you are a healthy volunteer.
- You have had recent lab tests (within the last week) if you have a plasma cell disorder.
- You are able to have a PET/CT scan.
- You do not have any other active cancer that is considered significant by the study doctor.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method that uses a special tracer to find multiple myeloma cells in the body. It may help doctors see the disease more clearly and guide treatment.
This study tests a new imaging method (PET-enabled dual-energy CT) to see if it can better show how multiple myeloma responds to CAR T-cell therapy. It may help doctors personalize treatment and catch changes early.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
Hear when a new Plasma Cell Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.